Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Zelenirstat in Adult Acute Myeloblastic Leukemia: NCT06613217 Clinical Landscape Report 2026
16 October 2026
NCT06613217 clinical landscape for Adult Acute Myeloblastic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Fludarabine Phosphate in Acute Myeloid Leukemia: NCT06613035 Clinical Landscape Report 2026
16 October 2026
NCT06613035 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in IDH1 Mutation Acute Myeloid Leukemia: NCT06611839 Clinical Landscape Report 2026
16 October 2026
NCT06611839 clinical landscape for IDH1 Mutation Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
DAT-2645 in Solid tumor: NCT06614751 Clinical Landscape Report 2026
16 October 2026
NCT06614751 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Relapse multiple myeloma: NCT06615479 Clinical Landscape Report 2026
16 October 2026
NCT06615479 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19 IL-10/IL15 CAR-NK Cells(The Second Affiliated Hospital Zhejiang University) in Idiopathic Inflammatory Myopathies: NCT06614270 Clinical Landscape Report 2026
16 October 2026
NCT06614270 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Dapirolizumab pegol in Systemic Lupus Erythematosus: NCT06617325 Clinical Landscape Report 2026
16 October 2026
NCT06617325 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carfilzomib in Recurrent Multiple Myeloma: NCT06622005 Clinical Landscape Report 2026
16 October 2026
NCT06622005 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Osteodex in Multiple Myeloma: NCT06616389 Clinical Landscape Report 2026
16 October 2026
NCT06616389 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rezatapopt in Myeloid Tumor: NCT06616636 Clinical Landscape Report 2026
16 October 2026
NCT06616636 clinical landscape for Myeloid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gemcitabine in Bladder Cancer: ACTRN12624001188527 Clinical Landscape Report 2026
16 October 2026
ACTRN12624001188527 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Relapsing acute myeloid leukemia: NCT06621212 Clinical Landscape Report 2026
16 October 2026
NCT06621212 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…